Therefore, msFGFR2c could inhibit the promoting effects of TGF-β, CTGF, and FGF-2 during lung fibrosis and has the potent clinical value for the treatment of pulmonary fibrosis. This evidence concerns the gene CCN2 and pulmonary fibrosis.